Introduction {#s1}
============

Trachoma is the leading infectious cause of blindness worldwide [@pmed.1001136-Mariotti1]. Recurrent episodes of ocular *Chlamydia trachomatis* infection in early childhood provoke chronic conjunctival inflammation (active trachoma). This inflammation can lead to conjunctival scarring, which may cause the eyelids to roll in (entropion) and the lashes to touch the surface of the eye (trachomatous trichiasis \[TT\]). Trichiasis is probably the main risk factor for the development of corneal opacification (CO) and visual impairment in trachoma. However, TT encompasses a very wide spectrum of disease. At one extreme there may be only a few metaplastic eyelashes without entropion. At the other extreme the whole eyelid can be entropic with all eyelashes and even the skin of the upper eyelid in contact with the ocular surface. The risk of developing CO is related to the severity of the trichiasis, and a distinction has been made between minor TT (one to five lashes touching the eye) and major TT (\>five lashes touching the eye) [@pmed.1001136-West1]--[@pmed.1001136-Reacher1].

Trachoma is endemic in around 50 countries, which are striving to control the disease through the implementation of the SAFE strategy: surgery for trichiasis, antibiotics for infection, and facial cleanliness and environmental improvements to reduce transmission [@pmed.1001136-Mariotti1],[@pmed.1001136-World1]. Currently, the World Health Organization (WHO) recommends that all individuals with one or more trichiatic eyelashes should be offered surgery, irrespective of lash location (central or peripheral) or the degree of entropion. The rationale for this recommendation is a practical one: patients with only a minor degree of trichiasis may not be seen again for a long time and there is a risk that the trichiasis will progress and cause visual impairment [@pmed.1001136-World1]. There is broad consensus that major TT should be treated surgically. However, for the management of minor TT the reality is often different, with many patients and clinicians preferring to defer surgery until the TT becomes more problematic. In some countries, such as The Gambia, there has been a policy of epilation (repeated removal of lashes with forceps) for minor trichiasis and surgery for major trichiasis, which predated the WHO guidelines [@pmed.1001136-Bowman1].

In recent years the number of individuals (mainly children) with active trachoma has declined significantly from 146 million in 1996 to 40 million in 2007, indicating that the A, F, and E components are effective [@pmed.1001136-Mariotti1],[@pmed.1001136-World2]. In contrast, the estimates of the number of people (mainly adults) living with untreated TT have not shown such encouraging declines: 10.6 million in 1996, 7.6 million in 2003, and 8.2 million in 2007 [@pmed.1001136-Mariotti1],[@pmed.1001136-World2]. Available data suggest that current surgical activity is probably keeping up with incident TT but may not be clearing the backlog. For example, in Ethiopia (the country with the most cases of TT) 1.3 million people were estimated to have TT in 2006, but only around 300,000 operations were performed in the last 5 y [@pmed.1001136-Mariotti1],[@pmed.1001136-Berhane1].

The reasons for this treatment gap are complex and multiple. Firstly, there may be insufficient services to address the backlog in many regions. Many of the health workers trained in TT surgery have been lost from programmes, may have conflicting clinical priorities, or do not have the instruments or consumables to perform surgery [@pmed.1001136-Lewallen1],[@pmed.1001136-Habtamu1]. Secondly, services may not be accessible to patients. Several studies have shown financial constraints, transport difficulties, and lack of time to be barriers to attending for surgery [@pmed.1001136-Bowman1],[@pmed.1001136-Courtright1]--[@pmed.1001136-Mahande1]. Thirdly, in many regions many patients (often the majority) refuse the offer of surgery, even when major barriers are addressed by the provision of free surgery at community level [@pmed.1001136-Bowman1],[@pmed.1001136-Oliva1]--[@pmed.1001136-Bowman2]. It is likely that in the next 5 y at least, the overwhelming majority of people with TT will not receive surgical treatment, irrespective of whether the TT is minor or major.

In trachoma endemic regions, TT surgery is usually provided by nonophthalmologists who receive about 2-wk training in one of the WHO recommended procedures: bilamellar tarsal rotation (BLTR) or posterior lamellar tarsal rotation (PLTR) [@pmed.1001136-Reacher2],[@pmed.1001136-World3]. Well-conducted surgery can be a permanent solution. However, trichiasis frequently recurs after surgery, particularly under operational conditions (as compared to clinical trials) where rates as high as 60% recurrence have been reported [@pmed.1001136-Burton1],[@pmed.1001136-Burton3]--[@pmed.1001136-West2].

Currently limited longitudinal data are available on which to base recommendations for individuals with minor TT. One cohort study of individuals with TT who refused surgery found that over a 4-y period, 37% progressed from minor to major TT and 5.1% developed new corneal opacity [@pmed.1001136-Burton2]. In a parallel cohort of patients from the same area who had accepted TT surgery, the comparable risks were 41% and 5.2%, respectively [@pmed.1001136-Burton3]. A second longitudinal study also found no difference in risk of developing new corneal opacity between people receiving TT surgery and those declining it, over a 1-y period [@pmed.1001136-Bowman3]. Studies from several trachoma endemic regions suggest that the majority of people with TT epilate [@pmed.1001136-Bowman1],[@pmed.1001136-Melese1]. Two cross-sectional studies have found that epilation is associated with a reduced risk of corneal opacity [@pmed.1001136-West1],[@pmed.1001136-Rajak1]. In high-income settings patients with a minor degree of trichiasis, such as metaplastic or misdirected lashes caused by lid margin disease, are often managed by repeated epilation. Epilation is simple for a trained helper to perform. However, it is an ongoing treatment that needs to be repeated when eyelashes regrow and should be conducted using good quality forceps.

In view of the prevalence of unoperated TT, the limited capacity of current surgical services, concerns over programmatic surgical outcomes, and the high rates of refusal, epilation might be an acceptable alternative to surgery for the management of minor TT. In this randomised trial we tested the hypothesis that epilation is noninferior to surgery for the treatment of minor TT.

Methods {#s2}
=======

Ethics Statement {#s2a}
----------------

The National Health Research Ethics Review Committee of the Ethiopian Ministry of Science and Technology, the London School of Hygiene and Tropical Medicine Ethics Committee, and Emory University Institutional Review Board approved the trial. Potential participants were provided with both written and oral information in Amharic about the trial. For those agreeing to participate, written informed consent in Amharic was required prior to enrolment. If the participant was unable to read and write, the information sheet and consent form were read to them and their consent recoded by witnessed thumbprint. An independent Data Safety Monitoring Committee reviewed the trial for patient safety and there were no deviations from the original protocol. No interim analyses for efficacy or futility were planned or conducted. The trial protocol is described in [Text S1](#pmed.1001136.s002){ref-type="supplementary-material"} and the CONSORT statement in [Text S3](#pmed.1001136.s003){ref-type="supplementary-material"}

Participants {#s2b}
------------

Eligible participants were individuals aged 18 y or over with previously unoperated minor trichiasis (\<six trichiatic eyelashes, some of which may have been epilated and were regrowing) who presented during a TT treatment campaign in rural villages in West Gojjam, Amhara Region, Ethiopia from March to June 2008. Exclusion criteria were previous eyelid surgery, medically unfit, or pregnancy (self-reported or clearly evident). The campaigns were advertised in local markets, churches, and schools. Additionally, health extension workers from the subdistricts (*kebele*) in the study area were trained to recognize trichiasis and visited each village in their *kebele* to identify patients. In individuals with bilateral TT, only one eye was randomly designated as the study eye and included in the analysis, although both eyes were treated.

Baseline Clinical Assessment {#s2c}
----------------------------

The clinical assessments and surgery were performed in government health centres. A field worker administered a questionnaire in Amharic. Height and weight were measured. Unaided and pinhole LogMAR visual acuities were measured at 4 m, using an ETDRS equivalent Tumbling-E LogMAR chart (Hong Kong Low Vision Centre). The testing distance was reduced to 2 or 1 m if necessary. For those unable to read the LogMAR chart at 1 m their visual acuity was tested by counting fingers at 1 m or hand movements at 0.5 m. For visual acuities of counting fingers or less, LogMAR values were attributed: counting fingers, 2.0; hand movements, 2.5; perception of light, 3.0; no perception of light, 3.5. No patients had spectacles for distance correction. In this report we present only unaided visual acuities. Ophthalmic examinations were conducted in a darkened room using 2.5× magnification loupes and a bright torch. A single ophthalmologist (SNR) performed all baseline examinations. The number of lashes touching the eye was counted ("lash burden") and also subdivided by the part of the eye contacted when looking straight ahead: cornea, lateral conjunctiva, or medial conjunctiva. Clinical evidence of epilation was identified by the presence of broken or newly growing lashes, or areas of absent lashes. Upper lid entropion was graded by assessing the degree of inward rotation of the eyelid margin ([Table S1](#pmed.1001136.s001){ref-type="supplementary-material"}). The degree of conjunctivilisation of the lid margin (anteroplacement of the muco-cutaneous junction) was assessed ([Table S1](#pmed.1001136.s001){ref-type="supplementary-material"}). The degree of corneal scarring was classified using a modified WHO detailed trachoma grading system (FPC) in which the degree of central corneal scarring (CC2) was subdivided into four, to provide more definition ([Table S1](#pmed.1001136.s001){ref-type="supplementary-material"}) [@pmed.1001136-Dawson1]. The Simplified WHO Trachoma Grading System corneal opacity measure (CO) is equivalent to CC2 and CC3 [@pmed.1001136-Thylefors1]. Tarsal conjunctival papillary inflammation, follicles, and scarring were classified using the WHO FPC grading system [@pmed.1001136-Dawson1]. Standardised high-resolution digital photographs were taken of each of these features.

Interventions {#s2d}
-------------

Following the baseline clinical assessment, participants were randomised to one of two intervention groups: surgery or epilation. The posterior lamella tarsal rotation procedure was used in all surgery cases [@pmed.1001136-World3]. Surgery was performed under local anaesthesia administered by subcutaneous infiltration of the upper eyelid: 2--3 ml of lidocaine 1%, with adrenaline. The lid was then everted and the posterior lamella (tarsal conjunctiva and tarsal plate) incised parallel to and 3 to 4 mm above the lid margin. The posterior and anterior (obicularis oculi and skin) lamellae were separated by blunt dissection. Three sets of 4/0 silk everting sutures (three-eighth circle, 16-mm cutting needles, Mersilk, Ethicon) were placed to externally rotate the lower border of the eyelid. Postoperatively, the operated eye was padded until the next morning and tetracycline eye ointment was self-administered twice a day for 2 wk. Five nurses, who had previously been trained in and were regularly performing TT surgery, performed the surgery in this trial. They were identified as the best surgeons from a larger group of nine during a 2-d standardisation workshop. This training was conducted by an experienced Ethiopian ophthalmologist (ABK), who had contributed to the development of the WHO TT surgeon certification manual [@pmed.1001136-World3]. The posterior lamellar tarsal rotation techniques of the five nurses were carefully observed and standardised to ensure that all performed the operation in the same way. The intraoperative quality of surgery was periodically reviewed during the course of the trial.

Individuals randomised to the epilation group were each given two pairs of high quality, machine-manufactured epilation forceps with round edged tips (for corneal safety) and flat, opposing plates to improve grip and reduce the likelihood of breaking lashes (Tweezerman). The patient and an accompanying adult ("epilator") with good near vision were trained to perform epilation. They observed the trainer epilate one or two lashes, with particular attention paid to removing the lash at its base to minimise broken stubs. The epilator was then observed epilating lashes and given advice on technique.

Follow-up Clinical Assessments {#s2e}
------------------------------

All participants in the surgery arm were seen 7--10 d postoperatively, at which point the sutures were removed and any complications noted and treated as needed. Several different ophthalmic nurses who did not take part in subsequent follow-ups conducted the 7--10-d suture removal follow-up. Follow-up assessments were conducted for both groups at 6, 12, 18, and 24 mo. On each occasion an ophthalmic examination was performed and digital photographs taken. Visual acuity was measured at 12 and 24 mo. The preoperative, 12-mo, and 24-mo examinations were conducted by a single ophthalmologist (SNR) and the 6- and 18-mo were conducted by a single ophthalmic nurse (EH). Neither of these examiners was involved in performing treatments in this trial. The examiners were standardised to each other and showed strong agreement between these two observers for the presence of trichiasis in a preliminary assessment of 200 eyes (kappa = 0.86). The presence/absence of notching (overcorrection of the central portion of the lid) and conjunctival granuloma were noted.

Any individual who showed evidence of disease progression, defined as five or more trichiatic lashes or corneal changes related to observed lashes at any follow-up examination, was immediately offered surgery (epilation arm) or repeat surgery (surgery arm) to be performed by a senior surgeon. These individuals continued to be followed up according to the trial protocol. Individuals in whom other ophthalmic pathology (e.g., cataract) was detected were referred to the regional ophthalmic services. New epilating forceps were provided as required. At the final follow-up (24 mo), all participants in the epilation arm were offered TT surgery.

Outcome Measures {#s2f}
----------------

The primary outcome measure was the proportion of individuals at any follow-up who had "failed," defined as either (1) five or more eyelashes touching the globe or (2) a history of surgery performed in the trial eye at any point during the follow-up period (in the case of the surgical arm this would be repeat surgery). The five or more lash threshold for failure was chosen to make it slightly more stringent than the inclusion criteria. A priori defined secondary outcome measures at 12- and 24-mo were: CO, visual acuity, entropion, conjunctival inflammation and symptoms of pain, subjective visual acuity, epiphora, and dryness.

Change in CO was assessed both by direct comparison of the 1- and 2-y photographs with the baseline photograph, and by comparison of the field grading scores. Photographs for each time point were viewed on a computer screen at about 10× magnification by a single masked observer (MJB). They were first graded using the trial grading system ([Table S1](#pmed.1001136.s001){ref-type="supplementary-material"}). Then the 1- and 2-y images were compared side by side with the baseline image, allowing the direct comparison of opacities to assess whether they had changed; these were graded as improved, no change, or worse. The baseline photographic and field CO scores showed good correlation (linear weighted kappa score 0.74; quadratic weighted kappa score 0.87).

Randomisation, Allocation Concealment, and Masking {#s2g}
--------------------------------------------------

Participants were randomly allocated to the epilation or surgery groups using a 1∶1 allocation ratio for each surgeon, using a computer-generated randomisation sequence with random block sizes. Randomisation was stratified by surgeon because of possible intersurgeon variability (each surgeon had a separate sequence). The London-based statistician held the master randomisation lists. The random allocation sequences for each surgeon were concealed in sequentially numbered, sealed, opaque envelopes, which were colour coded for surgeon and placed in separate containers for each surgeon. The person who prepared these envelopes was independent of all other aspects of the trial. Following the baseline examination, participants were allocated to the next available surgeon. A field worker was responsible for implementing the intervention assignment in a dedicated area, separated from those performing the preoperative examinations. The two individuals (SNR, EH) responsible for all the clinical outcome measurements were masked to the allocation. At follow-up, the trichiasis and corneal examination was performed and recorded before the eyelid was everted, so that the examiner was masked to whether surgery had been performed on the tarsal conjunctiva. The posterior lamella tarsal rotation technique used in this study does not involve a skin incision, so there were no external marks of previous surgery that could unmark the observer.

Statistical Methods {#s2h}
-------------------

A noninferiority trial design was chosen to investigate epilation in the management of minor trichiasis because of the potential secondary benefits of this intervention (greater acceptability and availability). Epilation is an ongoing treatment, which is performed when a trichiatic lash regrows. As such it is intrinsically less likely to be effective than surgery at always preventing lashes from touching the eye. In a noninferiority trial a slightly reduced clinical efficacy might be accepted if this is balanced by other secondary benefits; in the case of epilation these include greater acceptability and availability in an endemic population compared to surgery. We chose a noninferiority margin (Δ) of 10% at the outset of this trial as we considered this level to balance the considerations of clinical efficacy and secondary benefits.

The sample of 1,300 trial participants provided 90% power to detect noninferiority based on a two-sided 95% CI approach, assuming a 10% loss to follow-up over 2 y, a 5% failure rate in the surgery group, and a Δ of 10% between the epilation and surgery groups respectively [@pmed.1001136-Burton1],[@pmed.1001136-West3].

Data were double-entered into an Access (Microsoft) database and transferred to Stata 11 (StataCorp). Data were analysed by intention to treat. For participants who had bilateral treatment only the randomly designated "study eye" was included in the analysis. Patients were excluded from a specific analysis if they had missing data relevant to that analysis, as indicated in the results. Missing data were not imputed.

The 95% CI for the difference in the proportion of "failures" (proportion having ≥five lashes touching the eye or having surgery during follow-up period) between the two groups was estimated using exact methods. The primary outcome and binary secondary outcomes were compared between the two groups using logistic regression analyses to estimate the odds ratio (OR) and 95% CI. Time to failure was analysed with Kaplan-Meier survival curves, and Cox regression models to estimate hazard ratios (HRs) and 95% CI. Individuals who had reached endpoint at a previous time point or were permanently lost to follow-up from that time onwards were censored. The number of lashes touching the eye was analysed using zero-inflated Poisson regression to allow for the high proportion of eyes with no lashes touching [@pmed.1001136-Lee1]. The signed-rank test was used to analyse the difference in the number of lashes touching the eye between baseline and 24-mo follow-up. Changes in LogMAR visual acuity score were analysed by logistic regression. A multivariable logistic regression model was used to assess associations of failure with potential explanatory factors. Variables that were associated with the outcome on univariable analyses (*p*\<0.2) were retained in the multivariable model. For participants in the surgery arm, the cumulative risk of adverse surgical outcomes was estimated, including recurrence (≥one lashes touching the eye or clinical evidence of epilation), granuloma, and lid notching.

Results {#s3}
=======

Participant Recruitment and Flow {#s3a}
--------------------------------

Trial participants were recruited between March and June 2008. Several thousand people presented with eye complaints during the course of the surgical outreach campaign and were assessed for eligibility for this trial. The majority had other ophthalmic conditions such as cataract. A total of 1,300 consecutive eligible individuals were identified, all of whom consented to participate, were randomised, and received their allocated treatment (650 participants per group) ([Figure 1](#pmed-1001136-g001){ref-type="fig"}).

![Trial profile.](pmed.1001136.g001){#pmed-1001136-g001}

Primary outcome data are available for 637/650 (98.0%) participants in the epilation group and 641/650 (98.6%) participants in the surgery group ([Figure 1](#pmed-1001136-g001){ref-type="fig"}). Overall, 84.1% of participants were seen at all five scheduled visits over 24 mo: 517/650 (79.5%) in the epilation group and 576/650 (88.6%) in the surgery group. There were slightly fewer follow-up examinations in the epilation group (2,374/2,600 \[91.3%\]) compared with the surgery group (2,467/2,600 \[94.9%\], *p*\<0.001). 22 participants were not seen after baseline (13 epilation group, nine surgery group, *p* = 0.39).

Baseline Demographic and Clinical Characteristics {#s3b}
-------------------------------------------------

All participants were Ethiopians of Amharan ethnicity. Their mean age was 50.3 y and the majority (66.4%) were female. Baseline sociodemographic characteristics were generally balanced by randomisation group, although there were slightly fewer female participants in the epilation group than the surgery group (63.9% versus 68.9%) ([Table 1](#pmed-1001136-t001){ref-type="table"}). Clinical features were also balanced ([Table 1](#pmed-1001136-t001){ref-type="table"}) with the exception of central corneal opacity (CC2/CC3 or CO), which was more frequent in the epilation group (175; 26.9%) than the surgery group (137; 21.1%) at baseline.

10.1371/journal.pmed.1001136.t001

###### Baseline demographic and clinical characteristics of participants in each arm of the trial.

![](pmed.1001136.t001){#pmed-1001136-t001-1}

  Characteristic                                              Surgery, *n* = 650   Epilation, *n* = 650         
  ---------------------------------------------------------- -------------------- ---------------------- ------ --------------------
  ***Gender (female)***                                              448                 (68.9%)          415         (63.9%)
  ***Age (y)***                                                                                                 
  18--30                                                              69                 (10.6%)           67         (10.3%)
  30--39                                                             113                 (17.4%)          108         (16.6%)
  40--49                                                             156                 (24.0%)          150         (23.1%)
  50--59                                                             160                 (24.6%)          158         (24.3%)
  60--69                                                             112                 (17.2%)          122         (18.8%)
  70+                                                                 40                  (6.2%)           45          (6.9%)
  Mean (SD, 95% CI)                                                  49.9           (14.4, 48.8--51.0)    50.7   (14.5, 49.6--51.8)
  ***Illiterate***                                                   581                 (89.4%)          588          (90.5)
  ***BMI***, mean (SD, 95% CI)                                       19.9           (2.3, 19.7--20.1)     20.0   (2.4, 19.8--20.2)
  ***Study eye (right)*** [a](#nt101){ref-type="table-fn"}           319                 (49.1%)          302         (46.5%)
  ***Best corrected LogMAR VA in study eye***                                                                   
  −0.2 to 0.3                                                        243                 (37.7%)          211         (32.5%)
  0.3--0.7                                                           261                 (40.5%)          264         (40.7%)
  0.7--1.1                                                            83                 (12.9%)           89         (13.7%)
  1.1--2.0                                                            19                  (3.0%)           28          (4.3%)
  CF/HM/PL                                                            30                  (4.7%)           51          (7.9%)
  NPL                                                                 9                   (1.4%)           6           (0.9%)
  Not measurable[b](#nt102){ref-type="table-fn"}                      5                   (0.8%)           1           (0.2%)
  ***Entropion grade***                                                                                         
  0                                                                  276                 (42.5%)          292         (44.9%)
  1                                                                  258                 (39.7%)          254         (39.1%)
  2                                                                  113                 (17.4%)          102         (15.7%)
  3                                                                   3                   (0.5%)           2           (0.3%)
  4                                                                   0                   (0.0%)           0           (0.0%)
  ***Trichiasis (number of lashes touching eye)***                                                              
  Mean (95% CI)                                                      1.52              (1.43--1.62)       1.62      (1.52--1.72)
  None, epilating                                                    124                 (19.1%)          113         (17.4%)
  1--5 lashes                                                        526                 (80.9%)          537         (82.6%)
  ***Trichiasis position***                                                                                     
  Corneal ± peripheral                                               462                 (71.1%)          470         (72.3%)
  Peripheral only                                                    188                 (28.9%)          180         (27.7%)
  ***Lower lid TT (present)***                                        70                 (10.8%)           57          (8.8%)
  ***Corneal opacity -- field grading***                                                                        
  CC0, none                                                          345                 (53.1%)          330         (50.8%)
  CC1, peripheral                                                    168                 (25.9%)          145         (22.3%)
  CC2a, off centre faint                                              76                 (11.7%)           97         (14.9%)
  CC2b, off centre dense                                              9                   (1.4%)           15          (2.3%)
  CC2c, central faint                                                 30                  (4.6%)           43          (6.6%)
  CC2d, central dense                                                 11                  (1.7%)           14          (2.2%)
  CC3, total central dense                                            10                  (1.5%)           4           (0.6%)
  CC4, phthisis                                                       1                   (0.2%)           2           (0.3%)
  CO or CC2/CC3                                                      137                 (21.1%)          175         (26.9%)
  ***Papillary inflammation***                                                                                  
  None (P0)                                                           52                  (8.0%)           66         (10.2%)
  Mild (P1)                                                          248                 (38.2%)          248         (38.1%)
  Moderate (P2)                                                      297                 (45.7%)          282         (43.4%)
  Severe (P3)                                                         53                  (8.1%)           54          (8.3%)
  ***Conjunctival scarring***                                                                                   
  None (C0)                                                           3                   (0.5%)           4           (0.6%)
  Mild (C1)                                                           60                  (9.2%)           52          (8.0%)
  Moderate (C2)                                                      508                 (78.2%)          520         (80.0%)
  Severe (C3)                                                         79                 (12.2%)           74         (11.4%)
  ***Conjunctivilisation grade***                                                                               
  0                                                                   7                   (1.1%)           5           (0.8%)
  1                                                                   18                  (2.8%)           25          (3.9%)
  2                                                                  165                 (25.4%)          146         (22.5%)
  3                                                                  460                 (70.8%)          474         (72.9%)
  ***Lagophthalmos (present)***                                       10                  (1.5%)           9           (1.4%)
  **n** ***follow-up assessments***                                                                             
  0                                                                   9                   (1.4%)           13          (2.0%)
  1                                                                   10                  (1.5%)           13          (2.0%)
  2                                                                   12                  (1.9%)           28          (4.3%)
  3                                                                   43                  (6.6%)           79         (12.2%)
  4                                                                  576                 (88.6%)          517         (79.5%)

Participants with bilateral TT had one eye randomly selected as the trial eye.

Unable to cooperate with visual acuity measurement.

BMI, body mass index; CF, count fingers; HM, hand movements; PL, perception of light; NPL, no perception of light; SD, standard deviation; VA, visual acuity.

Primary Outcome {#s3c}
---------------

Overall, 98 individuals developed the primary outcome: 84 (13.2%) in the epilation group and 14 (2.2%) in the surgery group. In the epilation arm 74 had ≥five lashes and an additional ten participants had received repeat surgery elsewhere; in the surgery arm four had ≥five lashes and a further ten had received repeat surgery elsewhere. The difference in cumulative risk of failure was 11.0% (95% CI 8.1%--13.9%). The 95% CI includes the prestated margin of inferiority (Δ, 10.0%), so the trial is inconclusive and does not show evidence of noninferiority of epilation versus surgery, with respect to this prespecified noninferiority margin.

The rate of failure was greater in the epilation group (hazard ratio \[HR\] = 6.38, 95% CI 3.62--11.23) ([Figure 2](#pmed-1001136-g002){ref-type="fig"}). The mean number of lashes touching the eye at each visit was small ([Table 2](#pmed-1001136-t002){ref-type="table"}), but was significantly greater in the epilation group (*p*\<0.001). The number of lashes touching the eye reduced significantly between baseline and 24 mo in both groups (*p*\<0.001). Among patients in the epilation group, successful epilation (no lashes touching) at baseline was associated with reduced risk of failure (adjusted OR = 0.33, 95% CI 0.13--0.86) and baseline entropion of greater than grade 1 was associated with increased risk (adjusted OR = 1.72, 95% CI 0.98--3.02) ([Table 3](#pmed-1001136-t003){ref-type="table"}). There were too few failures in the surgery group to model.

![Kaplan Meier graph of time to failure.](pmed.1001136.g002){#pmed-1001136-g002}

10.1371/journal.pmed.1001136.t002

###### Clinical characteristics of participants in each arm of the trial at 12 and 24 mo.

![](pmed.1001136.t002){#pmed-1001136-t002-2}

  Characteristic                                                                 12 mo      24 mo                                                         
  ----------------------------------------------------------------------------- ------- -------------- ------ -------------- ------ -------------- ------ --------------
  ***Trichiasis - mean n lashes touching eye (95% CI)***                         0.11    (0.07--0.14)   1.00   (0.89--1.11)   0.09   (0.06--0.12)   0.95   (0.84--1.06)
  ***Best corrected LogMAR VA in trial eye***                                                                                                             
  −0.2 to 0.3                                                                     225      (36.4%)      189      (31.8%)      200      (32.7%)      167      (27.8%)
  0.3--0.7                                                                        261      (42.2%)      231      (38.8%)      272      (44.4%)      258      (43.0%)
  0.7--1.1                                                                        72       (11.6%)       95      (16.0%)       79      (12.9%)       93      (15.5%)
  1.1--2.0                                                                        26        (4.2%)       33       (5.6%)       25       (4.1%)       34       (5.7%)
  CF/HM/PL                                                                        30        (4.9%)       37       (6.2%)       28       (4.6%)       40       (6.7%)
  NPL                                                                              5        (0.8%)       10       (1.7%)       8        (1.3%)       8        (1.3%)
  ***LogMAR change (baseline to follow-up)***                                                                                                             
  \>0.3 worse                                                                     49        (8.0%)       66      (11.1%)       71      (11.7%)       87      (14.5%)
  0.1--0.3 worse                                                                  119      (19.3%)      108      (18.2%)      136      (22.4%)      137      (22.9%)
  Within 0.1 (same)                                                               308      (50.0%)      293      (49.3%)      277      (45.6%)      261      (43.6%)
  0.1--0.3 better                                                                 97       (15.8%)       97      (16.3%)       85      (14.0%)       75      (12.5%)
  \>0.3 better                                                                    43        (7.0%)       30       (5.1%)       38       (6.3%)       39       (6.5%)
  ***Entropion grade***                                                                                                                                   
  0                                                                               598      (96.5%)      223      (37.3%)      588      (95.9%)      167      (27.7%)
  1                                                                               19        (3.1%)      219      (36.6%)       18       (2.9%)      162      (26.9%)
  2                                                                                3        (0.5%)      154      (25.8%)       7        (1.1%)      272      (45.1%)
  3                                                                                0        (0.0%)       2        (0.3%)       0        (0.0%)       2        (0.3%)
  4                                                                                0        (0.0%)       0        (0.0%)       0        (0.0%)       0        (0.0%)
  ***Corneal opacity -- field grading***                                                                                                                  
  CC0, none                                                                       344      (55.5%)      275      (46.0%)      354      (57.8%)      290      (48.1%)
  CC1, peripheral                                                                 151      (24.4%)      147      (24.6%)      136      (22.2%)      140      (23.2%)
  CC2a, off centre faint                                                          70       (11.3%)      102      (17.1%)       67      (10.9%)       98      (16.3%)
  CC2b, off centre dense                                                          14        (2.3%)       18       (3.0%)       15       (2.5%)       25       (4.2%)
  CC2c, central faint                                                             22        (3.6%)       35       (5.9%)       18       (2.9%)       28       (4.6%)
  CC2d, central dense                                                             12        (1.9%)       16       (2.7%)       15       (2.5%)       14       (2.3%)
  CC3, total central dense                                                         6        (1.0%)       2        (0.3%)       7        (1.1%)       5        (0.8%)
  CC4, phthisis                                                                    1        (0.2%)       3        (0.5%)       1        (0.2%)       3        (0.5%)
  ***Corneal opacity change, baseline to follow-up -- photographic grading***                                                                             
  More corneal opacity                                                             7        (1.1%)       12       (2.0%)       25       (4.1%)       33       (5.5%)
  No change                                                                       602      (97.3%)      575      (96.8%)      579       94.6%)      561      (93.3%)
  Less corneal opacity                                                            10        (1.6%)       7        (1.2%)       8        (1.3%)       7        (1.2%)
  ***Corneal opacity change, baseline to follow-up -- field grading***                                                                                    
  \>3 grades worse                                                                 1        (0.2%)       2        (0.3%)       1        (0.2%)       1        (0.2%)
  3 grades worse                                                                   0        (0.0%)       0        (0.0%)       1        (0.2%)       1        (0.2%)
  2 grades worse                                                                  17        (2.9%)       27       (4.5%)       18       (2.9%)       22       (3.7%)
  1 grade worse                                                                   61        (9.8%)       75      (12.5%)       44       (7.2%)       77      (12.8%)
  No change                                                                       452      (72.9%)      418      (69.9%)      457      (74.6%)      436      (72.3%)
  1 grade better                                                                  72       (11.6%)       50       (8.4%)       71      (11.6%)       44       (7.3%)
  2 grades better                                                                 16        (2.6%)       23       (3.9%)       19       (3.1%)       19       (3.2%)
  3 grades better                                                                  1        (0.2%)       3        (0.5%)       1        (0.2%)       3        (0.5%)
  \>3 grades better                                                                0        (0.0%)       0        (0.0%)       1        (0.2%)       0        (0.0%)
  ***Papillary inflammation***                                                                                                                            
  None (P0)                                                                       172      (27.7%)      137      (22.9%)      328      (53.5%)      269      (44.6%)
  Mild (P1)                                                                       279      (45.0%)      251      (42.0%)      130      (21.2%)      130      (21.6%)
  Moderate (P2)                                                                   163      (26.3%)      191      (31.9%)      147      (24.0%)      186      (30.9%)
  Severe (P3)                                                                      6        (1.0%)       19       (3.2%)       8        (1.3%)       18       (3.0%)
  ***Conjunctivilisation grade***                                                                                                                         
  0                                                                               115      (18.6%)       7        (1.2%)       4       (12.1%)       5        (0.8%)
  1                                                                               88       (14.2%)       9        (1.5%)       63      (10.3%)       6        (1.0%)
  2                                                                               258      (41.6%)       83      (13.9%)      309      (50.4%)       54       (9.0%)
  3                                                                               159      (25.7%)      499      (83.4%)      167      (27.2%)      537      (89.2%)
  ***Lagophthalmos (present)***                                                    9       (1.45%)       11       (1.8%)       2        (0.3%)       1        (0.2%)

CF, count fingers; HM, hand movements; PL, perception of light; NPL, no perception of light; VA, visual acuity.

10.1371/journal.pmed.1001136.t003

###### Univariable and multivariable associations for reaching endpoint in the epilation group.
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  Variable                                                   OR      95% CI     *p*-Value
  -------------------------------------------------------- ------ ------------ -----------
  **Univariable analysis**                                                     
  No lashes at baseline (successful epilation)              0.27   0.11--0.68     0.005
  Entropion (\>grade 1) at baseline                         1.75   1.08--2.83     0.02
  Conjunctivalisation[a](#nt105){ref-type="table-fn"}       1.51   0.97--2.33     0.07
  Conjunctival bacteria at baseline                         1.00   0.51--1.98     0.99
  Persistent inflammation (grade 3+ for 3+ examinations)    1.70   1.08--2.67     0.02
  Female                                                    0.96   0.60--1.55     0.88
  Age\<30 y                                                 2.38   1.28--4.40     0.006
  Literate                                                  1.52   0.76--3.05     0.24
  BMI\<18                                                   1.48   0.86--2.54     0.15
  **Multivariable logistic regression model**                                  
  No lashes at baseline (successful epilation)              0.33   0.13--0.86     0.02
  Entropion (\>grade 1) at baseline                         1.72   0.98--3.02     0.06
  Conjunctivalisation                                       1.68   0.94--3.00     0.08
  Persistent inflammation (grade 3+ for 3+ examinations)    1.52   0.90--2.57     0.12
  Age\<30 y                                                 2.00   0.91--4.39     0.09
  BMI\<18                                                   1.47   0.79--2.75     0.22

Likelihood ratio test, no evidence of nonlinearity. Therefore combined measure of conjunctivilisation used in logistic regression model.

BMI, body mass index.

Visual Acuity {#s3d}
-------------

There was no evidence of a difference in change in visual acuity ([Table 2](#pmed-1001136-t002){ref-type="table"}) from baseline to follow-up between the two groups at either 12 mo (OR = 1.17, 95% CI 0.87--1.59) or 24 mo (OR = 1.16, 95% CI 0.88--1.53). There was similarly no evidence of a difference within randomisation group between the baseline and 24-mo visual acuity (paired *t*-test: surgery group *p* = 0.88; epilation group *p* = 0.99).

Corneal Opacification {#s3e}
---------------------

### Photograph comparison {#s3e1}

There was little change in CO, and no significant differences between the two groups. Comparison of the baseline and 24-mo follow-up corneal photographs found incident or progressive corneal opacity in 58 eyes (5.5% epilation; 4.1% surgery; *p* = 0.25).

### Field grading {#s3e2}

Comparison of baseline with follow-up field scores found moderate variation within both groups. The majority of patients in each arm had no change and most differences were of one grade ([Table 2](#pmed-1001136-t002){ref-type="table"}). There was a significant difference in change in CO between baseline and 24 mo, with a greater proportion of patients in the epilation arm having progression between baseline and 24 mo (16.8% epilation; 10.4% surgery; *p* = 0.001). However, using the detailed WHO FPC trachoma grading system for the analysis of the field scores there was no statistically significant difference between the two groups in the proportion of eyes with incident or progressive central CO between baseline and 24 mo (6.5% epilation; 4.7% surgery; *p* = 0.19).

Surgical Outcomes {#s3f}
-----------------

Trichiasis recurred (defined as one or more lashes touching the eye, or repeat surgery by another provider) in 114 (17.5%) individuals in the surgery group by 24 mo: 103 had minor TT recurrence, five had major TT recurrence, and six had repeat surgery from another provider. For comparison, in the epilation arm at 24 mo 298 (49.4%) had one or more lashes touching the eye. Surgery was associated with a marked reduction in entropion grade at 24 mo (4% versus 72% entropion grade ≥1; OR = 0.02, 95% CI 0.01--0.25) and lid margin conjunctivilisation grade at 24 mo (78% versus 98% conjunctivilisation grade ≥2; OR = 0.05, 95% CI 0.03--0.06) when compared to epilation. Adverse outcomes in the surgery arm are presented in [Table 4](#pmed-1001136-t004){ref-type="table"}.

10.1371/journal.pmed.1001136.t004

###### Postsurgical complications (a) at 7--10-d follow-up and (b) at any subsequent follow-up.
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  Outcome                                                       *n* Individuals  
  ------------------------------------------------------------ ----------------- ---------
  **(a) Early postoperative (7--10 d) complications**                            
  Undercorrection (lashes touching or nearly touching globe)           5          (0.8%)
  Overcorrection                                                       2          (0.3%)
  Infection/red eye                                                    3          (0.5%)
  Infection and undercorrection                                        1          (0.2%)
  Bleeding                                                             3          (0.5%)
  **(b) Complications during 2-y follow-up**                                     
  Recurrence                                                          105         (16.2%)
  Granuloma                                                           18          (2.9%)
  Notching                                                            29          (4.7%)

Symptoms {#s3g}
--------

Participants were asked about their symptoms ([Table 5](#pmed-1001136-t005){ref-type="table"}). At 12 mo postrandomisation, participants in the surgery arm recalled greater treatment pain than those in the epilation group (*p*\<0.001) but reported better subjective improvement in vision (*p*\<0.001) and less eye-watering (*p*\<0.001).

10.1371/journal.pmed.1001136.t005

###### Symptoms reported by participants at 12- and 24-mo follow-ups.
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  Characteristic                                    12 mo    24 mo                                         
  ------------------------------------------------ ------- --------- ----- --------- ----- --------- ----- ---------
  Vision                                                                                                   
  Better                                             484    (78.2%)   200   (33.4%)   545   (88.9%)   153   (25.4%)
  Same                                               87     (14.0%)   297   (49.7%)   59    (9.6%)    446   (74.1%)
  Worse                                              48     (7.8%)    101   (16.9%)    9    (1.5%)     3    (0.5%)
  Eye pain                                           272    (44.0%)   417   (69.7%)   353   (57.6%)   498   (82.6%)
  Eye watering                                       318    (51.4%)   378   (63.2%)   366   (59.7%)   423   (70.2%)
  Dry eye                                            138    (22.3%)   162   (27.1%)   134   (21.9%)   167   (27.7%)
  Treatment pain[a](#nt107){ref-type="table-fn"}                                                           
  None                                               49     (8.0%)    167   (33.3%)   ---             ---  
  Mild                                               274    (44.8%)   193   (38.5%)   ---             ---  
  Moderate                                           17     (2.8%)     6    (1.2%)    ---             ---  
  Severe                                             262    (42.8%)   136   (27.1%)   ---             ---  
  Don\'t remember                                    10     (1.6%)     0    (0.0%)    ---             ---  

As recalled at 12 mo.

Management at 24 Months {#s3h}
-----------------------

At 24 mo postrandomisation, 593/603 individuals in the epilation group had not had surgical treatment of their trichiasis. When offered free surgery, 185/593 (31%) accepted.

Discussion {#s4}
==========

We found no evidence that epilation is noninferior to surgery for the management of minor trichiasis, using a noninferiority margin of 10% for the difference in cumulative risk of failure. Therefore, in statistical terms, the trial is inconclusive. The proportion failing was 13.2% in the epilation group and 2.2% in the surgical group (difference = 11.0%; 95% CI 8.1%--13.8%). A relatively small proportion of patients in the epilation arm had evidence of progressive trichiasis; the rate of progression was slower than those previously reported [@pmed.1001136-Burton2],[@pmed.1001136-Bowman3]. Failure in the epilation arm was less frequent when the subject had been successfully epilating prior to enrolment and was more frequent if moderate entropion was present.

Overall, there was no significant difference in change in visual acuity between the groups. However, following surgery more people subjectively felt their vision had improved compared to those in the epilation group. This difference may have been due to watering of the eye (epiphora), which was reported more frequently by the epilation group, or disturbance caused by residual lashes. However, there could have also been an element of reporter bias, as participants who have received surgery may have felt more obliged to report an improvement to the team that provided the surgery. There was no significant change in vision over 2 y within either group. Two previous studies have reported a modest short-term improvement in visual acuity following surgery; however, both studies included many patients with more severe trichiasis; these people probably have greater potential for visual improvement [@pmed.1001136-Burton1],[@pmed.1001136-Woreta1].

Direct comparison of the baseline with 1- and 2-y corneal photographs found that there was very little change in corneal appearance and that there was no difference between the groups. The comparison of the longitudinal field grading scores suggested more variation occurred in both groups between time points, with slightly more progression in the epilation arm compared to the surgery arm. When the field scores were analysed using the WHO FPC grading system, there was no significant difference in progression between the groups. Our results are consistent with two previous longitudinal nonrandomised studies that examined corneal change in individuals with minor trichiasis, which found no difference in the development of new CO between those accepting surgery and those declining it (who were mostly epilating) [@pmed.1001136-Burton2],[@pmed.1001136-Burton3],[@pmed.1001136-Bowman3].

Overall, the authors consider that direct comparison of high-resolution digital photographs viewed at high magnification offers the most reliable measure of change in corneal appearance. Whilst it is possible that photographs are slightly less sensitive than careful direct clinical examination for very faint haze (which would not normally be considered trachomatous CO), it is unlikely that visually significant lesions would be missed. The kappa scores for the comparison of the field and photographic grading indicated good agreement between the observers. However, when a very detailed grading system such as the one developed for this study is used, some changes will lie at the boundary between two grades; even when all observations are performed by the same experienced ophthalmologist it is inevitable that some (unchanged) lesions will be graded slightly differently on different occasions, which we think accounts for much of the change reported by field scores. Of note, the two groups were not balanced at baseline for the amount of central corneal opacity (CO or CC2/CC3); by chance there was significantly more CO in those randomised to the epilation group, which may have led to more "observation noise" occurring in this group. This "observation noise" can be overcome by direct comparison of photographs, and explains why overall much less change was observed between the photographs. Photographs also offer the opportunity to detect change in lesions that may not result in a change in the categorical grade, so in this respect they are more sensitive than the categorical field grading.

Surgery, when there is no recurrence, offers a potentially long-lasting solution, whilst epilation is an ongoing intervention, which needs to be repeated when trichiatic lashes regrow. Therefore, it is to be expected that surgery would be better at preventing any eyelashes from touching the eye. However, surgery is not without problems. Although few individuals in the surgery arm reached endpoint, 16% developed recurrent TT. This number is slightly lower than that generally reported in trials and case series and is probably due to the relatively mild stage of the disease in the people recruited compared to other studies and the extra training and high surgical volume of the surgeons participating in this study [@pmed.1001136-Burton1],[@pmed.1001136-Burton3]--[@pmed.1001136-West2]. Lid margin notching, which is cosmetically unsatisfactory, was found in 5% of participants in the surgery arm and conjunctival granulomas requiring an additional minor procedure in 3%.

There are several considerations in interpreting the results of this trial. The choice of Δ in noninferiority trials is inevitably open to debate. In selecting a noninferiority margin of 10%, we took a relatively conservative view as to what would be programmatically acceptable, given the secondary benefits of acceptability and availability of epilation. If one were to only consider the clinical outcome in evaluating whether there is a place for epilation in the management of mild trichiasis, one would reject it, as the data from this study indicate that surgery is better at preventing lashes touching the eye. However, it should be borne in mind that the surgery in this trial was performed by surgeons selected for the high quality of their operating ability; they received refresher training and were routinely operating large numbers of cases. It is likely that the results they achieved were better than those that might be obtained under standard conditions. Therefore, under operational conditions the difference in clinical outcome between surgery and epilation would probably be smaller.

Moreover, the reality on the ground is that a large majority of the approximately 8 million people who have TT are not receiving surgical treatment. Given the enormous backlog of untreated cases and slow progress in addressing this, surgery is unlikely to be available to very large numbers of people living with trichiasis for at least the medium term. This situation is due to multiple challenges including insufficient numbers of health workers trained in TT surgery, who generally have conflicting responsibilities, limited resources, and barriers to accessing surgery such as low awareness of services and nonfinancial costs such as the time off work recuperating [@pmed.1001136-Lewallen1],[@pmed.1001136-Habtamu1]. Some of these challenges can and will be overcome with improved service organisation and investment. However, despite huge efforts to scale up trichiasis surgery services, for many patients the surgical services are likely to remain unavailable, inaccessible, or prohibitively expensive for the medium term [@pmed.1001136-Bowman1],[@pmed.1001136-Courtright1]--[@pmed.1001136-Mahande1]. Furthermore, many patients, particularly those with mild disease, decline the offer of surgery, even where this is being provided free of charge at community level, preferring to epilate [@pmed.1001136-Bowman1],[@pmed.1001136-Oliva1]--[@pmed.1001136-Bowman2]. Of note at the close of this trial all individuals in the epilation group were offered free, community-based surgery; only 31% accepted. Epilation is cheap, can be provided immediately during the first encounter of the patient with the service, delivered by volunteers with minimal training at community level to large numbers of people, and is generally acceptable to patients as a treatment modality.

Whether there is a role for epilation in trachoma control is ultimately a decision for individual national programmes, which would need to take into account a number of locally specific factors including the availability of staff and resources to provide a high quality surgical service and the acceptability of surgery to the population they serve.

There are several limitations to this study. Differential loss to follow-up is a potential source of bias in noninferiority trials, as one arm might have fewer opportunities to demonstrate failure. There were slightly fewer follow-up assessments in the epilation arm; however, this difference was not great and would be unlikely to have materially affected the trial outcome. There was a very slight difference between the two arms of the trial in the proportion that are female and, as discussed above, in the baseline prevalence of CO. These slight differences occurred by chance, as there were no errors in randomisation allocation. Detecting differences in change in both corneal disease and visual acuity may also require a longer follow-up period than the 2 y in this study.

Overall, the data from this trial and earlier nonrandomised studies suggest that, for people with minor trichiasis, repeated epilation is associated with visual acuity and corneal change outcomes that are comparable to surgery over a 2-y period [@pmed.1001136-Burton2],[@pmed.1001136-Burton3],[@pmed.1001136-Bowman3]. Where surgery is available and patients are willing to accept it, surgery should be performed, as the disease tends to progress, albeit quite slowly. However, we suggest that for individuals with minor trichiasis (who represent about half of all those with TT) epilation should be considered where surgery is either not available or declined by the patient.

Supporting Information {#s6}
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